Navigation Links
Translational Regenerative Medicine Forum sets stage for accelerating therapies to patients
Date:2/1/2010

Winston-Salem, N.C. -- The Regenerative Medicine Foundation today announced the first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.

The forum seeks to advance the field of regenerative medicine and health care innovation through the sharing of scientific discoveries, clinical and corporate best practices and business models. Reflecting the global scope of regenerative medicine, the meeting will feature keynote speakers and panelists providing a domestic and international perspective, including critical areas such as clinical advances, trial design, venture funding and obtaining regulatory approval.

"The Translational Regenerative Medicine Forum is designed to be the premiere international event for leaders in regenerative medicine translation, representing academic and clinical research, health care policy, venture investment and biotechnology industry interests," said Anthony Atala, M.D., director, Wake Forest Institute for Regenerative Medicine, and a forum speaker. "The body's natural capacity for healing has been known for generations, and the field of regenerative medicine exists to harness this natural healing process. It takes a collaborative approach to address the challenges of delivering regenerative medicine therapies to patients in a timely and cost-effective manner, and it is our expectation that this forum will bring together all the elements and fulfill the promise of the research."

Keynote speakers and plenary panelists include Steven Bauer, Ph.D., chief of the Cell and Tissue Therapy Branch, FDA Center for Biologics Evaluation and Research; Richard Caruso, Ph.D., founder and chairman of the board, Integra; Juan Enriquez, managing director, Excel Venture Management; Robert Klein, chairman, California Institute for Regenerative Medicine; Robert Lanza, M.D., chief scientific officer, Advanced Cell Technology; Lesa Mitchell, vice president
'/>"/>

Contact: Karen Richardson
krchrdsn@wfubmc.edu
336-716-4453
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Social Network for Translational Scientists Launched
2. ARVO Foundation and Pfizer Ophthalmics honor Carl B. Camras with translational research award
3. Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing, Emphasizing the Importance of Bringing Medical Innovation from Bench to Bedside
4. Translational Research: From Bench to Bedside Capitol Hill Breakfast Briefing Hosted by the Council for American Medical Innovation
5. ASH and EHA Jointly Announce Translational Research Training in Hematology Program
6. ASH and EHA jointly announce translational research training in hematology program
7. EAU Research Foundation organizes meeting in Amsterdam highlighting translational research results
8. Crescendo(tm), the Clinical and Translational Research Exchange, is Launched
9. Van Andel Research Institute of Michigan and Translational Genomics Research Institute of Arizona Undertake Unprecedented Alliance to Promote Science and Health
10. OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research
11. Rockefeller Universitys Center for Clinical and Translational Science funds 18 new pilot studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 01, 2014 The European gas chromatography systems ... analysis and forecast of revenue. The gas chromatography systems market ... is estimated to grow to around $247.6 million by 2018, ... Browse through the TOC of the European gas chromatography systems ... This also provides a glimpse of the segmentation of gas ...
(Date:8/1/2014)... According to a new market research report of ... Types, Applications (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace ... - Analysis & Forecast to 2010 - 2020", published ... to $1.42 Billion by 2020 at a CAGR of ... grow to $238.17 Million by 2020 at a CAGR ...
(Date:8/1/2014)... Society of America (GSA) the nation,s ... aging has chosen J. Jill Suitor, PhD, ... the Distinguished Career Contribution to Gerontology Award. , ... individual whose theoretical contributions have helped bring about ... original and elegant research designs addressing a significant ...
(Date:8/1/2014)... of America (GSA) the nation,s largest ... has chosen Madonna Harrington Meyer, PhD, of ... University of Luxembourg; and Philipp Hessel, MA, MSc, ... of Economics and Political Science as the 2014 ... , These distinguished honors recognize insightful and innovative ...
(Date:8/1/2014)... August 01, 2014 Lifeinsurancenomedicalexam.info has ... life insurance for clients who have high cholesterol levels. ... still find and qualify for no medical exam life ... requiring any background medical check-ups. , Since there are ... cholesterol level will qualify in just a few minutes. ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 2Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 3Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... ... educational stories, NEW YORK, May 12 ... Gamble Pharmaceuticals (P&G), has,selected seven winners for the Celebrating UC Success ... by ulcerative,colitis. Winners, stories reflect a wide variety of experiences with,ulcerative ...
... 12 FutureScripts(R), the premier,pharmacy benefit manager in ... . The website is a valuable tool for ... find key,information about the drugs on FutureScripts, formulary, ... "The new website allows our customers to find ...
... in French . , Montreal, May 12, 2008 ... in some cases, emotional and physical pain can linger for ... Universit de Montral graduate student Emma Duerden is inviting amputees ... study. , Our main goal is to better understand why ...
... homeless youth suggests that treating substance abuse and mental health ... the streets. , Instead, researchers found that creating more opportunities ... factors in reducing homelessness. , A study of 180 ... most social stability, such as those who attended school more ...
... is Disability Insurance Awareness Month; LIFE Foundation Reviews Common, Misconceptions to Encourage ... ... Needs, ARLINGTON, Va., May 12 If you were ... yourself,financially? The results of a new survey released today by the nonprofit,LIFE ...
... uncover ... system abuse, HORSEHEADS, N.Y., May ... in 2007. With so many recipients and,providers involved, the New York State ... abuse., Over the last two years, Salient Corporation, provider of the ...
Cached Medicine News:Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 2Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 3Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 4Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 5Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 6Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 2Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 3Health News:Homeless youth need more than treatment for substance abuse, study says 2Health News:Homeless youth need more than treatment for substance abuse, study says 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 2Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 4Health News:Salient Corporation's Performance Management Solution Helps NY State Counties Identify Medicaid Fraud, Waste, and Abuse 2
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
(Date:7/31/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... BIIB - Free Report ), Gilead (Nasdaq: GILD - ... Report ), AbbVie (NYSE: ABBV - Free Report ) ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Phase III,clinical trial evaluating the efficacy and safety ... of postmenopausal osteoporosis were,presented at the American Society ... In the non-inferiority study comparing risedronate 150,mg once ... sodium,tablets)] increases in bone mineral density (BMD) were ...
... Sept. 19 Rockwell Medical,Technologies, Inc. (Nasdaq: ... and,developer of concentrates and specialty pharmaceuticals focused ... that it has commenced,enrollment in its Phase ... a physiological iron-maintenance therapy drug. The ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... This unassayed control is intended ... manual and automated assay methods ... oxalate in human urine samples. ... requiring no reconstitution. This control ...
... Microbumin is a two-level control ... Clinitek Microalbumin Reagent Strips and Roche ... also suitable for turbidimetric immunoassays using ... and DCA 2000, Cobas, Diasorin SPQ ...
Medicine Products: